伦伐替尼联合帕博利珠单抗治疗经PD-1或PD-L1抑制剂单药或联合治疗确认进展的黑色素瘤的II期LEAP-004研究
LEAP-004是一项II期研究,评估伦伐替尼联合帕博利珠单抗治疗经PD-1/PD-L1抑制剂单药或联合治疗确认进展的不可切除III-IV期黑色素瘤患者。共103例患者入组,总人群客观缓解率为21.4%(95%CI 13.9-30.5),中位缓解持续时间8.3个月,中位无进展生存期4.2个月,中位总生存期14.0个月。3-5级治疗相关不良事件发生率45.6%,最常见为高血压(21.4%),1例患者死于治疗相关事件(血小板计数下降)。
要点
- 经PD-1/PD-L1抑制剂治疗后确认进展的晚期黑色素瘤患者,伦伐替尼联合帕博利珠单抗总人群ORR为21.4%。
- 既往接受抗PD-1联合抗CTLA-4治疗进展的30例患者中,ORR为33.3%。
- 3-5级治疗相关不良事件发生率为45.6%,最常见为高血压(21.4%)。
核心结论
- 伦伐替尼联合帕博利珠单抗在经PD-1/PD-L1抑制剂治疗后确认进展的晚期黑色素瘤患者中提供具有临床意义且持久的缓解,包括经抗PD-1联合抗CTLA-4治疗后进展的患者。
- 安全性特征与预期一致。
- 这些数据支持伦伐替尼联合帕博利珠单抗作为该高未满足需求人群的潜在方案。
研究设计与样本
- II期LEAP-004研究(ClinicalTrials.gov标识符NCT03776136),评估多激酶抑制剂伦伐替尼联合PD-1抑制剂帕博利珠单抗。
- 纳入不可切除III-IV期黑色素瘤患者,须在末次PD-1/L1抑制剂单药或联合其他治疗(包括CTLA-4抑制剂)给药后12周内确认疾病进展。
- 治疗方案:伦伐替尼20 mg口服每日一次,联合帕博利珠单抗200 mg静脉注射每3周一次,最多35剂,直至疾病进展或不可接受毒性。
- 主要终点为独立中心审查按RECIST第1.1版评估的客观缓解率。
- 共103例患者入组并接受治疗。
主要发现
- 中位研究随访时间为15.3个月。
- 总人群ORR为21.4%(95%CI 13.9-30.5),其中完全缓解3例(2.9%),部分缓解19例(18.4%)。
- 中位缓解持续时间为8.3个月(范围3.2-15.9+)。
- 既往接受抗PD-1联合抗CTLA-4治疗进展的30例患者中,ORR为33.3%。
- 总人群中位无进展生存期为4.2个月(95%CI 3.8-7.1),中位总生存期为14.0个月(95%CI 10.8-未达到)。
关键数值与推荐
- 3-5级治疗相关不良事件发生于47例(45.6%)患者,最常见为高血压(21.4%)。
- 1例患者死于治疗相关事件(血小板计数下降)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Effective treatments are needed for melanoma that progresses on inhibitors of programmed cell death protein-1 (PD-1) or its ligand (PD-L1). We conducted the phase II LEAP-004 study to evaluate the combination of the multikinase inhibitor lenvatinib and the PD-1 inhibitor pembrolizumab in this population (ClinicalTrials.gov identifier: NCT03776136). METHODS: Eligible patients with unresectable stage III-IV melanoma with confirmed progressive disease (PD) within 12 weeks of the last dose of a PD-1/L1 inhibitor given alone or with other therapies, including cytotoxic T-cell lymphocyte-associated antigen 4 (CTLA-4) inhibitors, received lenvatinib 20 mg orally once daily plus ≤ 35 doses of pembrolizumab 200 mg intravenously once every 3 weeks until PD or unacceptable toxicity. The primary end point was objective response rate (ORR) per RECIST, version 1.1, by independent central review. RESULTS: A total of 103 patients were enrolled and treated. The median study follow-up was 15.3 months. ORR in the total population was 21.4% (95% CI, 13.9 to 30.5), with three (2.9%) complete responses and 19 (18.4%) partial responses. The median duration of response was 8.3 months (range, 3.2-15.9+). ORR was 33.3% in the 30 patients with PD on prior anti-PD-1 plus anti-CTLA-4 therapy. The median progression-free survival and overall survival in the total population were 4.2 months (95% CI, 3.8 to 7.1) and 14.0 months (95% CI, 10.8 to not reached), respectively. Grade 3-5 treatment-related adverse events occurred in 47 (45.6%) patients, most commonly hypertension (21.4%); one patient died from a treatment-related event (decreased platelet count). CONCLUSION: Lenvatinib plus pembrolizumab provides clinically meaningful, durable responses in patients with advanced melanoma with confirmed PD on prior PD-1/L1 inhibitor-based therapy, including those with PD on anti-PD-1 plus anti-CTLA-4 therapy. The safety profile was as expected. These data support lenvatinib plus pembrolizumab as a potential regimen for this population of high unmet need.
引用
- Arance A, de la Cruz-Merino L, Petrella TM, et al. Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination. J Clin Oncol. 2022. PMID: 35867951. doi:10.1200/JCO.22.00221
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。